What complications can occur after a transperineal ultrasound-guided prostate biopsy performed without an identifiable target lesion?

Complications of Transperineal Prostate Biopsy Without Identifiable Lesion

Transperineal prostate biopsy, even without a target lesion, carries a low risk of serious complications but commonly causes minor bleeding and urinary symptoms, with the key advantage being near-zero rates of sepsis compared to transrectal approaches. 1

Infectious Complications

The transperineal approach demonstrates a significantly lower infection risk compared to transrectal biopsies:

• Zero or near-zero rates of sepsis have been consistently reported 1
• Urinary tract infections, epididymitis, orchitis, and prostatitis remain possible but rare 1
• Fever ≥37°C occurs in only 1.7% of patients, lasting approximately 1.8 days 2
• The lower infection rate makes this approach particularly valuable given the rising concern about drug-resistant E. coli infections that complicate transrectal biopsies 1

Bleeding Complications

Hematuria is the most common complication, occurring in a predictable pattern:

• 73.4% of patients experience hematuria, lasting an average of 4.5 days 2
• 42-59% report visible blood in urine across multiple studies 3, 4
• Perineal bleeding occurs in 7.1%, lasting approximately 2.2 days 2
• Hematospermia affects 13-14.4% of patients 2, 4
• Clot retention occurs in approximately 2% of patients on anticoagulation versus 0.2% in controls 3

Critical Caveat for Anticoagulated Patients

Patients on anticoagulation or antiplatelet therapy experience similar complication rates, though taking two or more anti-thromboembolic agents is the only significant risk factor for increased bleeding 3. Even in these patients, no severe (Grade III or higher) complications occur, and discontinuation of anticoagulation is not necessary 3.

Urinary Complications

Urinary retention represents the most clinically significant non-infectious complication:

• 1.1% require indwelling catheterization for Grade 2 urinary retention 2
• Prostate volume is the independent predictor of urinary retention risk (p = 0.001) 2
• Dysuria affects 15.7%, lasting approximately 3.1 days 2
• Urinary tract pain occurs in 49.5%, lasting 2.4 days 2

Important: The transperineal approach may be associated with higher rates of urinary retention compared to transrectal approaches 1, making this the primary trade-off for the reduced infection risk.

Pain and Discomfort

Pain is common but manageable:

• Perineal pain affects 35.5%, lasting 3.5 days 2
• 31% report pain requiring analgesia in some series 4
• Only 18% actually need analgesia post-procedure 4
• Headache occurs in 22.1% (likely related to spinal anesthesia when used), lasting 3.4 days 2

Rare but Serious Complications

While extremely uncommon, case reports document:

• Urethral corpus cavernosum pseudoaneurysm with persistent bleeding and DIC 5
• Intraperitoneal bleeding, particularly in patients with prior focal therapy or smaller prostates with scarring 6
• Acute retention requiring admission (approximately 1 in 171 patients) 4

Hospitalization Risk

• 30-day hospitalization risk is 2.7-fold increased after any prostate biopsy 1
• Hospitalization prolongation occurs in 4.0% of patients on anticoagulation versus 0.4% of controls 3
• However, 70% of admissions are infection-related 1, making the transperineal approach advantageous

Clinical Algorithm for Risk Assessment

Pre-biopsy factors to evaluate:

1. Prostate volume (larger = higher retention risk) 2
2. International Prostate Symptom Score (higher = increased hematuria risk, p = 0.014) 2
3. Number of anti-thromboembolic agents (≥2 = increased bleeding) 3
4. Prior prostate procedures (increases rare complication risk) 6

Key Advantage: The absence of an identifiable lesion does not change the complication profile—systematic sampling carries the same risks as targeted biopsies, but the near-zero sepsis rate makes transperineal biopsy safer than transrectal approaches regardless of whether a target exists 1.